Hematopoietic cell transplantation for sickle cell disease: updates and future directions.

ABSTRACT: Excellent outcomes in hematopoietic cell transplantation (HCT) from HLA-identical siblings, improvements in conditioning regimens, novel graft-versus-host disease prophylaxis, and the availability of alternative donors have all contributed to the increased applicability and acceptability of HCT for sickle cell disease (SCD). In young children with symptomatic SCD with an available HLA-identical related donor, HCT should be carefully considered. HCT from alternative donors is typically undertaken only in patients with severe symptoms, causing or likely to cause organ damage, and in the context of clinical trials. Patients undergoing HCT for SCD require careful counseling and preparation. They require careful monitoring of unique organ toxicities and complications during HCT. Patients must b

SUBMITTER: Krishnamurti L 

PROVIDER: S-EPMC8791142 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature